NICE has recommended cemiplimab (Libtayo) for recurrent or metastatic cervical cancer after platinum-based chemotherapy, supported by improved survival and quality-of-life outcomes from the Phase 3 EMPOWER-Cervical 1 trial.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cemiplimab (Libtayo) marketed in the UK by Regeneron UK Limited, as a treatment option for adults with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-based chemotherapy and who have not previously received immunotherapy.
The recommendation makes the anti-PD-1 immunotherapy available through the National Health Service (NHS) in England, providing a new treatment option for a patient population with limited therapeutic choices. NICE estimates that around 90 patients each year could be eligible for the treatment.
Cervical Cancer Treatment Landscape
Recurrent or metastatic cervical cancer remains a difficult-to-treat disease associated with poor survival outcomes and substantial impact on quality of life. Patients whose cancer progresses after platinum-based chemotherapy often face limited treatment options, and responses to conventional chemotherapy are typically short-lived.
Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody that enhances the immune system’s ability to recognize and attack cancer cells. By inhibiting the PD-1 pathway, the therapy restores anti-tumor immune activity and has demonstrated clinical benefit across several advanced malignancies.
EMPOWER-Cervical 1 Trial
NICE based its recommendation primarily on findings from the Phase 3 EMPOWER-Cervical 1 study (NCT03257267), which compared cemiplimab with investigator-choice single-agent chemotherapy in patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy.
The study showed a clinically meaningful improvement in overall survival. Patients receiving cemiplimab achieved a median overall survival of 11.7 months compared with 8.5 months for those treated with chemotherapy. Survival benefits were sustained over time, with more than twice as many patients alive at 24 months in the cemiplimab group.
Beyond survival, the immunotherapy delayed disease progression and delivered better quality-of-life outcomes during treatment. Patients experienced fewer treatment-related burdens compared with chemotherapy, an important consideration for individuals managing advanced disease and ongoing care needs.
The overall safety profile was consistent with the known effects of PD-1 inhibitors and supported a favorable benefit-risk assessment.
NICE Assessment and Clinical Benefit
NICE’s independent appraisal committee concluded that cemiplimab provides meaningful improvements in both progression-free outcomes and overall survival compared with standard chemotherapy.
Helen Knight, Director of Medicines Evaluation at NICE, noted that treatment options remain limited for patients with recurrent or metastatic cervical cancer and highlighted the evidence showing that cemiplimab can both extend survival and improve quality of life relative to conventional chemotherapy.
Patient and clinical experts involved in the appraisal process also emphasized the importance of reducing treatment-related toxicity and minimizing hospital visits, factors that can significantly affect daily living for people with advanced cancer.
NHS Access and Implementation
Eligible patients will gain immediate access to cemiplimab through NHS funding arrangements. The treatment will initially be funded through the Cancer Drugs Fund before transitioning to routine NHS commissioning 90 days after publication of the final NICE guidance.
The recommendation establishes cemiplimab as a new immunotherapy option for previously treated recurrent or metastatic cervical cancer and expands access to a therapy that has demonstrated both survival and quality-of-life benefits in a setting with substantial unmet medical need.
Reference
New treatment option recommended for recurrent or metastatic cervical cancer | NICE
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.